Ferroptosis Inhibitors

Migration, Crosslink

📗 Cite This Artifact

←

Home / Artifacts / Ferroptosis Inhibitors

📖

Ferroptosis Inhibitors

active

wiki page Created: 2026-04-02T07:19:00 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-ferroptosis-inhibitors

📖 Wiki Page

therapeutics616 wordssynced 2026-04-02

Introduction

Ferroptosis Inhibitors is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

[Ferroptosis](/entities/ferroptosis) is an iron-dependent form of regulated cell death characterized by lipid peroxidation. Ferroptosis inhibitors represent a novel therapeutic strategy for neurodegenerative diseases, as this cell death pathway has been implicated in Alzheimer's disease, Parkinson's disease, Huntington's disease, and ALS. [@stockwell2017]

Pathway Diagram

...

Introduction

Pathway Diagram

Mermaid diagram (expand to render)

Knowledge graph relationships for ferroptosis (750 total edges in KG)

Overview

Ferroptosis Biology

What is Ferroptosis?

Ferroptosis is a non-apoptotic cell death process characterized by:

Iron-dependent accumulation of lipid reactive oxygen species (ROS)
Glutathione peroxidase 4 (GPX4) inactivation
Lipid peroxidation of membrane phospholipids
Distinct morphological features (no nuclear fragmentation)

Key Pathways

GPX4-dependent pathway:

GPX4 reduces lipid peroxides to prevent ferroptosis
System Xc- imports cystine for glutathione synthesis
Glutathione is required for GPX4 function

Iron metabolism:

Iron catalyzes Fenton reactions generating [ROS](/entities/reactive-oxygen-species)
Ferritin stores iron to prevent toxicity
Transferrin receptor regulates iron uptake

Therapeutic Applications

Alzheimer's Disease

Ferroptosis contributes to:

Neuronal death in AD brain
Iron accumulation in AD brain
Lipid peroxidation in [neurons](/entities/neurons)

Inhibitors may:

Protect neurons from death
Reduce oxidative damage
Slow disease progression

Parkinson's Disease

Ferroptosis in PD:

Iron accumulation in substantia nigra
Dopaminergic neuron vulnerability
Lipid peroxidation in PD brain

Inhibitors show:

Protection of dopaminergic neurons
Reduced iron-induced toxicity
Improved motor function

Huntington's Disease

Ferroptosis in HD:

Mutant [huntingtin](/proteins/huntingtin-protein) affects iron metabolism
Enhanced neuronal vulnerability
Lipid peroxidation in striatum

Inhibitors:

Reduce mutant [huntingtin](/genes/htt) toxicity
Protect striatal neurons

ALS

Ferroptosis in ALS:

Motor neuron vulnerability
Iron dysregulation
Enhanced oxidative stress

Inhibitors:

Protect motor neurons
Delay disease progression

Drug Candidates

| Compound | Mechanism | Stage | Company |
|----------|-----------|-------|--------|
| Ferrostatin-1 | Lipid ROS scavenger | Preclinical | N/A |
| Liproxstatin-1 | Liproxstatin-1 | Preclinical | N/A |
| SRS6-16 | GPX4 activator | Preclinical | N/A |
| Vitamin E | Antioxidant | Phase 2 | Various |
| Deferoxamine | Iron chelator | Phase 2 | Various |
| Deferasirox | Iron chelator | Phase 2 | Novartis |

Clinical Trials

NCT03225893: Deferoxamine for Alzheimer's disease (completed)
NCT03716570: Iron chelation for Parkinson's disease (completed)

Challenges and Limitations

[BBB](/entities/blood-brain-barrier) penetration: Ensuring CNS delivery

Iron homeostasis: Balancing iron chelation

Optimal timing: Treatment window

Selectivity: Targeting specific neuronal populations

Future Directions

Development of brain-penetrant ferroptosis inhibitors
Combination with antioxidants
Gene therapy approaches
Biomarker development

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[ClinicalTrials.gov](https://clinicaltrials.gov/)

Background

The study of Ferroptosis Inhibitors has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

[Dixon SJ, et al, (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22539075/)

[Stockwell BR, et al, (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28985560/)

[Weiland A, et al, (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31313223/)

[Maher P, et al, (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32393280/)

[Do Van B, et al, (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/26738387/)

[Wu C, et al, (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33704679/)

[Conrad M, et al, (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29836720/)

[Angeli JP, et al, (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28332939/)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia](/hypothesis/h-seaad-v4-26ba859b) — 0.73 · Target: ACSL4
[ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia](/hypothesis/h-seaad-v4-26ba859b) — 0.73 · Target: ACSL4
[Extracellular Matrix Stiffness Modulation](/hypothesis/h-725c62e9) — 0.53 · Target: PIEZO1
[Senescence-Induced Lipid Peroxidation Spreading](/hypothesis/h-7957bb2a) — 0.57 · Target: GPX4/SLC7A11
[Circadian-Gated Maresin Biosynthesis Amplification](/hypothesis/h-83efeed6) — 0.60 · Target: ALOX12
[Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Therapy](/hypothesis/h-ac55ff26) — 0.58 · Target: ALOX15
[Mitochondrial SPM Synthesis Platform Engineering](/hypothesis/h-13bbfdc5) — 0.47 · Target: ALOX5
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC

Related Analyses:

[Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)](/analysis/SDA-2026-04-02-gap-seaad-v4-20260402065846) 🔄
[Epigenetic reprogramming in aging neurons](/analysis/SDA-2026-04-02-gap-epigenetic-reprog-b685190e) 🔄
[Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) 🔄
[Tau propagation mechanisms and therapeutic interception points](/analysis/SDA-2026-04-02-gap-tau-prop-20260402003221) 🔄
[Senolytic therapy for age-related neurodegeneration](/analysis/SDA-2026-04-01-gap-013) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving Ferroptosis Inhibitors discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

therapeutics-ferroptosis-inhibitors

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-ferroptosis-inhibitors
kg_node_id	None
entity_type	therapeutics
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-5e8664bfdccb
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-ferroptosis-inhibitors'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

Incoming

Outgoing

100

0 supporting 0 contradicting 0 neutral

View full evidence profile →

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found

This artifact has no version history yet.

Linked Artifacts (154)

mentions🔬SPMs (resolvins, protectins, maresins) from omega-3s may pro100%

mentions🔬Senolytics targeting p16/p21+ senescent astrocytes and micro100%

mentions🧪Extracellular Matrix Stiffness Modulation70%

see_also🧪Extracellular Matrix Stiffness Modulation70%

see_also🧪ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro70%

mentions🧪ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro70%

mentions🧪Senescence-Induced Lipid Peroxidation Spreading60%

mentions🧫Ferroptosis Validation in Parkinson's Disease60%

mentions🧫Proposed experiment from debate on Senolytics targeting p16/60%

see_also📖ABCB1 (MDR1) - ATP Binding Cassette Subfamily B Member 160%

see_also📖ACSL4 Gene - Acyl-CoA Synthetase Long Chain Family Member 460%

see_also📖ABCA7 (Redirect)60%

see_also📖acc-chronic-pain60%

mentions🧪Interfacial Lipid Mimetics to Disrupt Domain Interaction50%

mentions🧪Grid Cell-Specific Metabolic Reprogramming via IDH2 Enhancem50%

mentions🧪Blood-Brain Barrier SPM Shuttle System50%

mentions🧪HDAC3-Selective Inhibition for Clock Reset50%

mentions🧪Synthetic Biology Rewiring via Orthogonal Receptors50%

mentions🧫Peroxisome Dysfunction Validation in Parkinson's Diseas50%

mentions🧪APOE Isoform Expression Across Glial Subtypes50%

mentions🧪Blocking AGE-RAGE Signaling in Enteric Glia to Prevent Neuro50%

mentions🧪Mitochondrial Calcium Buffering Enhancement via MCU Modulati50%

mentions🧫S-equol-induced ferroptosis mechanism in TNBC cells50%

mentions🧪Lipid Droplet Dynamics as Phenotype Switches50%

mentions🧪Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Th50%

mentions🧪Competitive APOE4 Domain Stabilization Peptides50%

mentions🧪Extracellular Vesicle Biogenesis Modulation50%

mentions🧪Senescence-Associated Myelin Lipid Remodeling50%

mentions🧪Targeted APOE4-to-APOE3 Base Editing Therapy50%

mentions🧪Chromatin Accessibility Restoration via BRD4 Modulation50%

mentions🧪Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Ci50%

mentions🧪APOE4 Allosteric Rescue via Small Molecule Chaperones50%

mentions🧪Matrix Stiffness Normalization via Targeted Lysyl Oxidase In50%

mentions🧪Astrocytic Connexin-43 Upregulation Enhances Neuroprotective50%

mentions🧪Magnetosonic-Triggered Transferrin Receptor Clustering50%

mentions🧪Multi-Modal Stress Response Harmonization50%

mentions🧪Transcriptional Autophagy-Lysosome Coupling50%

mentions🧪APOE-Dependent Autophagy Restoration50%

mentions🧫Gandouling protection against brain injury in Wilson's 50%

mentions🧪Metabolic Circuit Breaker via Lipid Droplet Modulation50%

mentions🔬Cell type vulnerability in Alzheimers Disease (SEA-AD transc50%

mentions🧪Phase-Separated Organelle Targeting50%

mentions🧪Selective APOE4 Degradation via Proteolysis Targeting Chimer50%

mentions🧪Circadian-Gated Maresin Biosynthesis Amplification50%

mentions🧪Senescent Cell Mitochondrial DNA Release50%

mentions🧪Axonal RNA Transport Reconstitution50%

mentions🧪Mitochondrial SPM Synthesis Platform Engineering50%

mentions🧪Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulat50%

mentions🧪AMPK hypersensitivity in astrocytes creates enhanced mitocho50%

mentions🧪Mitochondrial Transfer Pathway Enhancement50%

mentions🧪VCP-Mediated Autophagy Enhancement50%

mentions🧪Astroglial Gap Junction Coordination via Connexin-43 Phospho50%

mentions🧪Selective HDAC3 Inhibition with Cognitive Enhancement50%

mentions🧪TFAM overexpression creates mitochondrial donor-recipient gr50%

mentions🧫s:** - ALOX15 overexpression in healthy astrocytes should be44%

mentions🔬What are the mechanisms underlying blood-brain barrier trans40%

mentions🔬What are the mechanisms underlying tdp-43 phase separation t40%

mentions🔬What are the mechanisms underlying mitochondrial transfer be35%

mentions🔬What are the mechanisms underlying astrocyte reactivity subt35%

mentions🔬CRISPR-based therapeutic approaches for neurodegenerative di35%

mentions🔬What are the mechanisms underlying microglia-astrocyte cross35%

mentions🔬Epigenetic reprogramming in aging neurons35%

mentions🔬What are the mechanisms underlying epigenetic clocks and bio35%

mentions🔬What are the mechanisms underlying what are the mechanisms b35%

mentions🔬What are the mechanisms underlying rna binding protein dysre35%

mentions🔬What are the mechanisms underlying digital biomarkers and ai35%

mentions🔬What are the mechanisms underlying neuroinflammation resolut35%

mentions🔬What are the mechanisms underlying selective vulnerability o35%

mentions🔬What are the mechanisms underlying mechanistic role of apoe 35%

mentions🔬What are the mechanisms underlying mitochondrial transfer be35%

mentions🔬What are the mechanisms underlying autophagy-lysosome pathwa35%

mentions🔬What are the mechanisms underlying senolytic therapy for age35%

mentions🔬Investigate prion-like spreading of tau pathology through co35%

mentions🔬What are the mechanisms underlying perivascular spaces and g35%

Reference URLs

Canonical (singular)/artifact/wiki-therapeutics-ferroptosis-inhibitorscanonical

Canonical (plural, REST)/artifacts/wiki-therapeutics-ferroptosis-inhibitorsalias

API (JSON)/api/artifacts/wiki-therapeutics-ferroptosis-inhibitorsapi

Citation — BibTeX/artifacts/wiki-therapeutics-ferroptosis-inhibitors/cite?fmt=bibtexexport

Citation — RIS/artifacts/wiki-therapeutics-ferroptosis-inhibitors/cite?fmt=risexport

Citation — CSL-JSON/artifacts/wiki-therapeutics-ferroptosis-inhibitors/cite?fmt=cslexport

Embed this artifact

Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.

HTML iframe

<iframe src="http://scidex.ai/artifact/wiki-therapeutics-ferroptosis-inhibitors?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>

Markdown link

[Ferroptosis Inhibitors](http://scidex.ai/artifact/wiki-therapeutics-ferroptosis-inhibitors)

Direct URL

http://scidex.ai/artifact/wiki-therapeutics-ferroptosis-inhibitors

Preview

🔄 Adjacent Artifacts Recommended based on your interests

💬 Discussion

Loading comments...

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Ferroptosis Inhibitors

Introduction

Pathway Diagram

Introduction

Pathway Diagram

Overview

Ferroptosis Biology

What is Ferroptosis?

Key Pathways

Therapeutic Applications

Alzheimer's Disease

Parkinson's Disease

Huntington's Disease

ALS

Drug Candidates

Clinical Trials

Challenges and Limitations

Future Directions

See Also

External Links

Background

Allen Brain Atlas Resources

References

Related Hypotheses

Pathway Diagram

💬 Discussion